Abbott Laboratories $ABT Shares Acquired by BXM Wealth LLC

BXM Wealth LLC boosted its position in Abbott Laboratories (NYSE:ABT) by 612.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 28,772 shares of the healthcare product maker’s stock after purchasing an additional 24,735 shares during the quarter. BXM Wealth LLC’s holdings in Abbott Laboratories were worth $3,605,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of ABT. Secure Asset Management LLC lifted its holdings in shares of Abbott Laboratories by 4.0% during the 4th quarter. Secure Asset Management LLC now owns 15,257 shares of the healthcare product maker’s stock valued at $1,912,000 after acquiring an additional 593 shares in the last quarter. BAM Wealth Management LLC increased its holdings in Abbott Laboratories by 11.5% in the 4th quarter. BAM Wealth Management LLC now owns 3,307 shares of the healthcare product maker’s stock valued at $414,000 after purchasing an additional 342 shares in the last quarter. St. Clair Advisors LLC raised its position in Abbott Laboratories by 8.2% in the fourth quarter. St. Clair Advisors LLC now owns 16,410 shares of the healthcare product maker’s stock valued at $2,056,000 after purchasing an additional 1,250 shares during the period. Nvwm LLC lifted its stake in shares of Abbott Laboratories by 4.3% during the fourth quarter. Nvwm LLC now owns 15,041 shares of the healthcare product maker’s stock worth $1,885,000 after purchasing an additional 616 shares in the last quarter. Finally, Westwood Wealth Management purchased a new stake in shares of Abbott Laboratories in the fourth quarter worth about $278,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Sanford C. Bernstein decreased their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Evercore reduced their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Citigroup lowered their price target on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. BTIG Research dropped their price target on shares of Abbott Laboratories from $140.00 to $131.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Finally, Raymond James Financial decreased their price objective on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $135.68.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares in the company, valued at $16,918,253.66. This represents a 0.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, February 4th. The shares were purchased at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last ninety days. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Down 0.0%

Shares of NYSE:ABT opened at $102.84 on Monday. The company’s fifty day moving average is $109.48 and its two-hundred day moving average is $120.94. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. Abbott Laboratories has a 1-year low of $100.88 and a 1-year high of $139.06. The stock has a market capitalization of $179.11 billion, a price-to-earnings ratio of 27.65, a price-to-earnings-growth ratio of 1.64 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.